IGF2BP2 and central nervous system cancer: This mechanism suggests targeting IGF2BP2 SUMOylation could offer new therapeutic approaches for glioma.[126] Similarly, YTHDF2 is SUMOylated at lysine 571, a modification that enhances its affinity for m6A‐modified mRNAs without affecting its ubiquitination or localization.